# Filing Detail

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-022192
Filing Date
2025-03-10
Accepted
2025-03-10 16:06:58
Documents
106
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ANNUAL REPORT | ea0232483-20f_purple.htm iXBRL | 20-F | 2800603
2 | DESCRIPTION OF SHARE CAPITAL | ea023248301ex2-1_purple.htm | EX-2.1 | 105434
3 | INSIDER TRADING POLICY | ea023248301ex4-23_purple.htm | EX-4.23 | 48979
4 | LIST OF SUBSIDIARIES OF THE REGISTRANT | ea023248301ex8-1_purple.htm | EX-8.1 | 5801
5 | CERTIFICATION | ea023248301ex12-1_purple.htm | EX-12.1 | 10203
6 | CERTIFICATION | ea023248301ex13-1_purple.htm | EX-13.1 | 4330
7 | CONSENT OF SOMEKH CHAIKIN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, A MEMB | ea023248301ex15-1_purple.htm | EX-15.1 | 2021
8 | GRAPHIC | image_001.jpg | GRAPHIC | 97310
9 | GRAPHIC | image_002.jpg | GRAPHIC | 44748
10 | GRAPHIC | image_003.jpg | GRAPHIC | 45546
| Complete submission text file | 0001213900-25-022192.txt |  | 10426767

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | XBRL SCHEMA FILE | ppbt-20241231.xsd | EX-101.SCH | 98731
12 | XBRL CALCULATION FILE | ppbt-20241231_cal.xml | EX-101.CAL | 52279
13 | XBRL DEFINITION FILE | ppbt-20241231_def.xml | EX-101.DEF | 346142
14 | XBRL LABEL FILE | ppbt-20241231_lab.xml | EX-101.LAB | 624157
15 | XBRL PRESENTATION FILE | ppbt-20241231_pre.xml | EX-101.PRE | 355297
109 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0232483-20f_purple_htm.xml | XML | 1505866

Mailing Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104
Business Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104 97239333121
PURPLE BIOTECH LTD. (Filer) CIK: 0001614744 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-37643 | Film No.: 25723704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)